• Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

  Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

  Evidence, Lobular, MammaPrint, Neoadjuvant, Other

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More

kevin2024-03-25T10:51:13-07:00November 1st, 2012|Evidence, Lobular, MammaPrint, Neoadjuvant, Other|

Read More

• Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

  Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

  Evidence, Healthcare Economics, MammaPrint, Other

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More

kevin2024-03-25T10:52:27-07:00June 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

Read More

• Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode

  Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode

  Evidence, Healthcare Economics, MammaPrint, Other

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode

PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb Read More

kevin2024-03-25T10:54:31-07:00February 22nd, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

Read More

• Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

  Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

  Evidence, Healthcare Economics, MammaPrint, Other

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub Read More

kevin2024-03-25T10:55:06-07:00January 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

Read More

• Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

  Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

  Evidence, MammaPrint, Other

Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers

PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub Read More

kevin2024-03-25T10:55:45-07:00December 2nd, 2011|Evidence, MammaPrint, Other|

Read More

• The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

  The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

  Adjuvant, Evidence, MammaPrint, MINDACT

The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue Read More

kevin2024-03-07T11:48:20-08:00December 1st, 2011|Adjuvant, Evidence, MammaPrint, MINDACT|

Read More

• 

  Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

  Gallery

  Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

  Adjuvant, Evidence, MammaPrint

Use of a Genomic Test (MammaPrint™) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

PUBLICATION: Arch Gynecol Obstet (2011) 283: 597. https://doi.org/10.1007/s00404-010-1454-9. AUTHORS: Kunz, Read More

kevin2024-03-25T10:56:57-07:00March 1st, 2011|Adjuvant, Evidence, MammaPrint|

Read More

• Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

  Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

  Evidence, MammaPrint, Other, Validation

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher Read More

kevin2024-03-07T11:49:23-08:00February 11th, 2011|Evidence, MammaPrint, Other, Validation|

Read More

• Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer

  Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer

  Evidence, Healthcare Economics, MammaPrint, Other

Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer

PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen Read More

kevin2024-03-25T10:57:22-07:00December 21st, 2010|Evidence, Healthcare Economics, MammaPrint, Other|

Read More

• Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature

  Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature

  Evidence, HER2-positive, MammaPrint, Other

Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature

PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788–1793. Published Read More

kevin2024-03-07T11:51:48-08:00December 7th, 2010|Evidence, HER2-positive, MammaPrint, Other|

Read More